Sign In
Buy BICX
$0.260
-0.0400 (-13.33%)
At Close: Jul 31, 2026
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
08:30am, Tuesday, 09'th Jan 2024
ANAHEIM, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and r
BioCorRx Reports Business Update for the Third Quarter of 2023
12:52pm, Tuesday, 14'th Nov 2023
ANAHEIM, CA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and r
Company Hopes in 30 Days to Begin Making Its Drug Candidate Available to Help Patients and Address Public Health Crisis ANAHEIM, CA, Aug. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx In
BioCorRx Reports Business Update for the Second Quarter of 2023
04:34pm, Monday, 14'th Aug 2023
On Track to Meet 2023 Regulatory Milestones ANAHEIM, CA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative
ANAHEIM, CA, July 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and r
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd
08:30am, Friday, 27'th Jan 2023
Presentation on Thursday, February 2, 2023 at 2:00 PM ET
BioCorRx to Present at the LD Micro Main Event XV on October 25th
11:30am, Monday, 24'th Oct 2022
Anaheim, California--(Newsfile Corp. - October 24, 2022) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disord
BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference
09:30am, Tuesday, 06'th Sep 2022
ANAHEIM, CA, Sept. 06, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and
BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference
08:30am, Tuesday, 06'th Sep 2022
ANAHEIM, CA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and
BioCorRx to Present at the LD Micro Invitational XII on June 7th
09:00am, Tuesday, 31'st May 2022
ANAHEIM, CA, May 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and
BioCorRx to Participate in Two Upcoming Conferences
08:30am, Tuesday, 22'nd Mar 2022
ANAHEIM, CA, March 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse a
BioCorRx to Present at the Q1 Investor Summit Conference on March 9th
08:30am, Wednesday, 02'nd Mar 2022
Anaheim, California--(Newsfile Corp. - March 2, 2022) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders
BioCorRx Appoints Drug Delivery Expert Jie Shen, Ph.D., to Scientific Advisory Board
02:00pm, Thursday, 09'th Dec 2021 Intrado Digital Media
ANAHEIM, CA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the Company) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced the appointment of Dr. Jie Shen to the Scientific Advisory Board (SAB).
BioCorRx (OTCMKTS:BICX) Share Price Passes Above 50 Day Moving Average of $4.51
07:30am, Wednesday, 08'th Dec 2021 Transcript Daily
Shares of BioCorRx Inc. (OTCMKTS:BICX) crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $4.51 and traded as high as $4.68. BioCorRx shares last traded at $4.66, with a volume of 536 shares traded. The businesss 50-day moving average price is $4.51 and []
BioCorRx to Participate in the Benzinga All Access Event on December 2nd
01:30pm, Wednesday, 24'th Nov 2021 Intrado Digital Media
ANAHEIM, CA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the Company) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO and Director of BioCorRx, Inc. and Brady Granier, President and Director, CEO of BioCorRx Pharmaceuticals, will be participating in the Benzinga All Access event taking place on December 2, 2021.
